Beamtree Holdings Ltd · ASX:BMT
Beamtree — Investor Presentation (August 2023)
29 slides from Beamtree's investor presentation, Aug 24, 2023
Slide 1: FY23 Annual Results
FY23 Annual Results 24 August 2023
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 24 August 2023. This presentation may contain statements that are, or may be deemed to be, forward looking sta
Slide 3: FY23 Highlights
FY23 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: FY23 Financial Highlights
FY23 Financial Highlights 25% PCP * 38% 78% 64% $8.8M PCP PCP PCP Annual recurring Reported International Operating Loss Cash Revenue Revenue Revenue $22.8M $22.8M* $7.3M $(1.4)M +$0.8M Operating cashflow *Reported recurring revenue growth +51% • Prior Corresponding Period “PCP” 3 Copyright © Beamtr
Slide 5: FY23 Divisional Highlights
FY23 Divisional Highlights Diagnostic Technology: AI Clinical Decision Support: Indirect Sales: via partnership with Abbott Laboratories Inc. Scientific endorsement of Beamtree AI in transforming • Dec 22 signed a new distribution partnership with Abbott. patient safety • Growing pipeline going into
Slide 6: FY23 Divisional Highlights
FY23 Divisional Highlights Coding Assistance and Data Quality Analytics and Knowledge Networks Audit & Advisory – lead generation toward product Sales momentum implementation • 45% of group revenue, +95% renewal rates • Saudi - awarded $1m health information management • Revised contract with larges
Slide 7: Annual Recurring Revenue (ARR) Trend
Annual Recurring Revenue* (ARR) ($’M) Trend + ~25% organic YOY growth ~$60M 22.8 21.0 20.1 19.1 18.2 $22.8M 17.3 16.8 FY23 2026 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Diagn. Coding CDS KN *Annual Recurring revenue defined as last month of each quarter’s recurring licence fee, volume
Slide 8: Investment in FY22 providing operating leverage in FY23
Investment in FY22 providing operating leverage in FY23 1H FY22 2H FY22 1H FY23 2H FY23 • FY22 was a year of investment with organic opex growth of 85% or (0.5) $6m centred on ADI AI product ($1.6M), international sales Q4 delivered resources ($1.5M), product & (0.9) $0.1m technology including cyber
Slide 9: FY24 Outlook
FY24 Outlook Continued focus on cost Management reaffirms long management with cost Beamtree targeting to term outlook of delivering Targeting FY24 organic growth % targeted to be deliver a positive operating annual recurring revenue of revenue growth of +20% lower than revenue growth profit in FY24
Slide 10: Long Term Horizon – Reaffirm Conviction
Long Term Horizon – Reaffirm Conviction Main Drivers of Growth: ~70% of the growth will come from overseas market $22.8M FY23 9 Copyright © Beamtree Holdings Limited – All Rights Reserved
Slide 11: Beamtree Strategy
Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 10
Slide 12: Creating a better future for health
Creating a better future for health As a global AI health technology company, we empower organisations to deliver exceptional patient care. We strive to create a better future for health by turning data into insights and action through automation. Copyright © Beamtree Holdings Limited – All Rights R
Slide 13: Learning Health Systems
Learning Health Systems Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency.
Slide 14: About Us
About Us 25+ years of experience Australian company with Supporting healthcare Cutting-edge use of AI and Australian IP globally machine learning Diagnostic Technology Clinical Decision Support in Coding Assistance & Analytics & Knowledge leaders acute care Data Quality Networks 13
Slide 15: The Problems We Help Solve
The Problems We Help Solve Tackle unwarranted Offer revenue Promote transparency Drive automation variation assurance Address equity Bridge knowledge gaps Increase efficiency, Improve quality of access and resource reducing errors of data allocation Copyright © Beamtree Holdings Limited – All Rights
Slide 16: Our product segments
Our product segments Copyright © Beamtree Holdings Limited – All Rights Reserved 15
Slide 17: Key Areas, Key Products and What They Do
Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Leverages scarce clinical Clinical rules to automate Removes duplication for experts resources through Recurring expert decision making in Diagnostics in providing diagnostic results automating a
Slide 18: Highlights of FY23
Highlights of FY23 17 Copyright © Beamtree Holdings Limited – All Rights Reserved
Slide 19: FY23 Financial Results
FY23 Financial Results Copyright © Beamtree Holdings Limited – All Rights Reserved 18
Slide 20: FY23 Summary Profit and Loss
FY23 Summary Profit and Loss Highlights FY21 FY22 FY23 Change P&L ($M) Actual Actual Actual FY23-22 Licence, subs. + usage fees revenue 6.2 14.2 21.6 51% Group Revenue +38% Consulting & other service fees revenue 2.2 2.3 1.2 (48%) Total Revenue 8.4 16.5 22.8 38% Annual recurring revenue (ARR) 6.7 18
Slide 21: Annual Recurring Revenue (ARR) Growth
Annual Recurring Revenue* (ARR) Growth ($’M) • Organic ARR growth across all +25% PCP segments 22.8 • $4.6m organic growth more than double organic ARR in 4.6 2.0 18.2 FY22 9.5 • Growth in ARR driven by new international contracts in Diagnostics (~50%) and 6.7 domestic growth in Coding and Knowledge
Slide 22: Reported Revenue Growth
Reported Revenue Growth ($’M) +38% PCP (+20% organic • 52% of growth driven by PCP) international activities with notable wins in South Africa, +14% organic 22.8 FY23 3-year PCP* Growth CAGR Kingdom of Saudi Arabia, Canada and the UK 16.5 7.3 +78% PCP +101% +15% organic 4.1 • International growth 78
Slide 23: Operating Expenses
Operating Expenses ($’M) +18% PCP (~7% organic PCP) • 86% of cost increase in FY23 +174% PCP (~85% organic PCP) driven by employee related 24.2 expenses. 20.6 +9% YOY 6.9 • 22% increase in employee costs 29% of total 6.3 or driven by investment in additional capabilities and skills required to suppo
Slide 24: Operating Profit and Reported EBITDA
Operating Profit and Reported EBITDA Operating Profit ($M) Reported EBITDA ($M) 1.0 1H FY22 2H FY22 1H FY23 2H FY23 (0.5) (0.9) Q4 delivered FY21 FY22 FY23 $0.1m (1.4) operating profit (1.2) (2.3) (2.6) FY22 Operating loss $4m FY23 Operating loss $1.4m FY21 FY22 FY23 Operating Profit 0.9 (4.0) (1.4)
Slide 25: Balance Sheet
Balance Sheet FY21 FY22 FY23 CONSOLIDATED GROUP ($M) Actual Actual Actual Current assets Strong balance sheet: Cash & cash equivalents 14.1 6.4 8.8 Trade & other receivables 2.1 6.9 5.3 • $8.8m Cash Contracts 1.1 0.1 0.3 Total current assets 17.4 13.3 14.4 • $5.3m Receivables Non-current assets Prop
Slide 26: Cashflow – Positive Operating Cashflow in FY23
Cashflow – Positive Operating Cashflow in FY23 FY21 FY22 FY23 CONSOLIDATED GROUP ($M) Actual Actual Actual $0.8m positive operating CASHFLOWS FROM OPERATING ACTIVITIES cashflow in FY23 (versus Receipts from customers 7.4 17.5 25.4 +$2.3m outflow in FY22) Payments to suppliers and employees (7.7) (20
Slide 27: FY24 Outlook
FY24 Outlook Copyright © Beamtree Holdings Limited – All Rights Reserved 26
Slide 28: FY24 Outlook
FY24 Outlook Continued focus on cost Management reaffirms long management with cost Beamtree targeting to term outlook of delivering Targeting FY24 organic growth % targeted to be deliver a positive operating annual recurring revenue of revenue growth of +20% lower than revenue growth profit in FY24
Slide 29: Thank you
Thank you Copyright © Beamtree Holdings Limited – All Rights Reserved 28
Beamtree Holdings — Investor Presentation (August 2023) on 6ix